W HAT role, if any, serotonin (5 hydroxytryptamine) may play in the pathogenesis of essential hypertension is open to question.' Although admittedly often pressor when given in large dosages intravenously, the effects of serotonin on blood pressure are always variable. [2] [3] [4] [5] Indeed, when given intravenously it does not cause a generalized vasoconstriction characteristic of the hypertensive state, but rather produces vasoconstriction in some vascular areas, for example, in the kidney, and vasodilatation in others, for example, in the skin. Moreover, the concentration of serotonin is not increased in the plasma of hypertensive patients. Indeed in the one disease in which its concentration may be greatly increased, namely in carcinoid cases, hypertension is not one of the usual clinical features of the syndrome.' However, the concentration of serotonin in plasma may not be the critical factor, since it is a readily metabolizable hormone, and its true action may depend more upon its momentary liberation, or activation, in certain local areas, for example, within the brain, than upon its circulation within the blood stream.7
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Numerous hypotheses have been advanced for the functions of serotonin within the body. These include a styptic or hemostatic function upon its liberation from the platelets of the blood, a tonic function in the bowel upon its liberation by the chromaffin cells of the intestinal wall, a blood pressure-regulating function through its circulation or perhaps its local liberation within the vascular system, and finally a central nervous system-regulating function through its activation within the brain. However, none of these hypotheses is above serious criticism. This is but natural considering that we Table 1 shows the results of BAS adininistration in 25 hypertensive patients given the drug alone in alternation with a placebo. The average of the control blood pressures in this group was 201/121 mm. Hg. The average blood pressure during treatment with BAS (average dose, 72 mg. a day for 18 weeks) was 18.3110, or about 20/10 mm. Hg lower than the average during the control periods. Furthermore, it is interesting that while the blood pressure was reduced by 20/10 mm. Hg or more in 9 of the 23 patients, it was not reduced at all in 7. Table 2 shows the effects of BAS when added to a regimen of other hypotensive drugs. These drugs included rauwolfia (or reserpine), veratrum, Apresoline, and occasionally a blocking agent (particularly pentolinium or hexamethonium). The average of the blood pressures before any treatment whatsoever in these patients was 220/124. With the other hypotensive drugs used, the average of the blood pressures was 202/116. When BAS was added to these drugs the blood pressure was 192/109, a negligible decrease in the average. However, it was noted in 6 of these 20 when BAS was added that the blood pressure was reduced by 20/10 mm. Hg or more, while in 11 of the 20 it was not affected in any way. Figure 1 shows one of the more striking results from the administration of BAS to a hypertensive patient. It demonstrates that the drug had both a hypotensive and a bradycrotic effect as compared with the placebo, and in this patient the medication also had a symptomatically beneficial action. Figure 2 shows the blood pressure effects in another patient given BAS alone as compared with reserpine alone and a combination of BAS with reserpine. The combination of BAS and reserpine had a more definite hypotensive effect than either agent used alone. Figure 3 demonstrates the blood pressure effect of BAS given in combination with 3 New England Medical Center for the information on 2 of these patients. Side Effects. The side effects of BAS used in hypertensive patients resemble remarkably those of reserpine. They included sedation, or a "relaxed," "sleepy," or even "depressed" feeling. Abdominal cramps with some urgency of bowel movement were frequently noticed. There was no diarrhea but rather an urgent or explosive stool or two a day. Bradyeardia also was noted by some of the patients who complained of less palpitation on the medication than off. Nasal stuffiness was noted in a number of instances but was never so severe or troublesome as that produced by rauwolfia or reserpine. BAS, like reserpine, caused a decrease in libido in a few male patients.
Of the side effects, "sedation" or "tranquilization"" was the most definite and tended to limit the dosage of the drug or require its omission as patients became "too sleepy" or "depressed." In some patients, however, this sedative effect was beneficial, particularly in one who had had intractable insomnia for 15 years, which was not relieved by any medication, including barbiturates and reserpine. On 100 mg. of BAS a day this patient slept soundly from 9 p.m. to 7 a.m., and yet was fully alert during the day.
In some of the patients a type of tolerance appeared to develop on continued use of BAS. This was noted not only in the blood pressure effect, which occasionally was lost after an initial good hypotensive action, but also in the development of a state of constipation. Whether or not this was a flaccid or a spastic type of constipation was not clear from the history of the patients. One other late, possible side effect was noted in some patients, namely a tendency to loss of appetite and weight on continued medication. This was commented upon particularly by some patients who were trying to reduce and found it definitely easier to do when taking BAS. This was in contradistinction to the increased appetite and tendency to gain weight frequently noted by patients taking reserpine.
DIscussIoN
An antiserotonin approach to the problem of the treatment of hypertension, first suggested by Woolley and Shaw in 1952,8 is appealing, not only because of the known "tonic" effect of serotonin on smooth muscle in general, and blood vessels in particular, but also because of the possible relationship of antiserotonin effects to the known hypotensive actions of rauwN-olfia and reserpine. Reserpine as an analog of yohimbine and indeed as an indole derivative could be considered to be a serotonin analog and hence possibly an antimetabolite of serotonin. Furthermore, *when reserpine is given to animals it depletes the natural stores of serotonin in the braiil, the platelets of the blood, and the intestinal tract.7' 11, 12 Indeed, since the clinical action of reserpine (sedation) in such animals parallels the duration of its effect on serotonin concentrations in the brain, its action has been supposed to be dependent on its serotonin effect. This would account not only for the delay in the appearance of the clinical action of reserpine but also for the persistence of its action long after its administration has been stopped.
In our own pharmacologic studies of the hemodynamic and respiratory effects of serotonin,4-5 we have not been able to demonstrate a clear-cut "antiserotonin" effect of reserpine given orally over long periods to patients for the treatment of hypertension. However in 1 of 5 patients retested with intravenous serotonin while taking reserpine, it was found that serotonin had a hypotensive effect during reserpine administration which it did not have during placebo control periods. A similar observation has been made in animals. '3 Likewise in our pharmacologic studies of the antiserotonin effects of BAS it, was not possible to demonstrate a clear-cut antiserotonin effect during chronic oral administration of BAS as it was after a single intravenous administration of 50 mg. BAS. However, in patients taking BAS orally for hypertension, there was a definite decrease in the subjective sensations of mental distress, and tingling and burning in the throat and face after an intravenous dose of serotonin as compared with the effects of the same dose during the control period. This subjective relief was similar to that noticed by patients with carcinoid in whom symptoms supposedly due to serotonin were decreased by BAS.
Our impression was that BAS given orally in the dosages that were tolerated for long periods in hypertensive patients (100 to 200 mg. per day) had only slight "antiserotoninl" qualities, as measured by our objective methods. The only possibly significant~'antiserotoniin action" noted was a lessening of the symptoms produced by intravenous serotonin as already mentioned. Therefore, whether its "antiserotonin effect" had anything to do with the apparently beneficial hypotensive action of BAS observed in some of the hypertensive patients was not clear. Some other associated effect such as sedation, bradyeardia, or a combination of 2 of these "side effects" rather than a direct "ant iserotonin" action of BAS could have been responsible for the hypotensive results.
It is interesting that BAS is the first of the clinically useful hypotensive agents synthesized because of theoretical rather than empirical considerations. In this respect it differs from the other agents discovered by accident to be useful in hypertension, such as potassium thiocyanate, hydralazinie, veratrum, and rauwolfia. However, as already suggested, it is only fair to say that the clinical usefulness of BAS, if any, may not prove to depend upon its "antiserotonin" effects. Indeed, the same may be said of reserpine. Nevertheless, an "antiserotonin approach" would seem to be a valuable one to pursue in connection with such drugs in the hope that not only better agents but a better understanding of their actions would result. This approach would be equally valid in the field of the "tianquilizing" as of the "antihypertensive" drugs. 
SUMMARY

